1. Home
  2. CCEL vs ELUT Comparison

CCEL vs ELUT Comparison

Compare CCEL & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

N/A

Current Price

$5.06

Market Cap

41.8M

Sector

Health Care

ML Signal

N/A

Logo Elutia Inc.

ELUT

Elutia Inc.

N/A

Current Price

$0.82

Market Cap

35.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CCEL
ELUT
Founded
1989
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.8M
35.6M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
CCEL
ELUT
Price
$5.06
$0.82
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.6K
★ 75.6K
Earning Date
10-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 146.77
EPS
★ 0.23
N/A
Revenue
★ $25,384,279.00
$12,293,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.04
★ N/A
Revenue Growth
★ 9.76
N/A
52 Week Low
$2.72
$0.50
52 Week High
$5.45
$1.39

Technical Indicators

Market Signals
Indicator
CCEL
ELUT
Relative Strength Index (RSI) 54.73 51.67
Support Level $3.05 $0.75
Resistance Level $5.45 $0.87
Average True Range (ATR) 0.31 0.07
MACD -0.00 -0.00
Stochastic Oscillator 52.42 67.16

Price Performance

Historical Comparison
CCEL
ELUT

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About ELUT Elutia Inc.

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

Share on Social Networks: